Page last updated: 2024-11-13

hexa-d-arginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID57358476
SCHEMBL ID19267519
MeSH IDM000605672

Synonyms (16)

Synonym
hexa-d-arginine amide
673202-67-0
d-argininamide, d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-
hexa-d-arginine ,
CS-7595
AKOS024458307
n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithinamide
DTXSID90724127
furin inhibitor ii
SCHEMBL19267519
HY-P1028
NCGC00505008-01
BS-17319
D71119
d-argininamide d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine
d-argininamided-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The influence of furin suppression on HBV replication and the effect of CMK combined with nucleoside analog entecavir (ETV) on HBV replication and HBeAg secretion was investigated in HepG2."( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.
Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014
)
0.4
" Moreover, the viral replication-enhancing effect of CMK was abrogated by ETV and ETV combined with CMK reduced HBV replication and HBeAg secretion simultaneously."( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.
Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014
)
0.4
" Nucleotide/nucleoside analogs combined with furin inhibitors may be a potential easy way to realize the dual goals of the antiviral therapy for chronic hepatitis B in the future."( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.
Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.90 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]